1. Why am I taking OMJJARA?
OMJJARA contains the active ingredient momelotinib, which is a type of medicine known as a protein kinase inhibitor.
OMJJARA blocks the action of certain proteins, called Janus Kinases (JAK1, JAK2) and ACVR1. By doing so, it can relieve the symptoms of myelofibrosis. With myelofibrosis, the bone marrow is replaced by scar tissue, and small proteins called cytokines are released in large numbers. The abnormal marrow can no longer produce enough normal blood cells, the spleen can become enlarged, and patients get symptoms such as fever, night sweats, bone pain, and itching.
OMJJARA is used to treat adults with myelofibrosis, a rare form of blood cancer affecting the bone marrow, who also have anaemia (a reduced number of red blood cells), reduce the size of their spleen, and relieve other symptoms related to the disease.
Myelofibrosis may be:
- primary myelofibrosis, which develops in people who have not had problems with their bone marrow before;
- secondary myelofibrosis, which develops in people who have other blood cancers, causing their body to produce too many red blood cells or blood cells called platelets (post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis).
Published by MIMS April 2025